BioVie Inc (BIVI) Options

Well apparently this is another small cap bio dead dog. Rip...Sheesh..

Getting perky for turn upside!

BIVI is waking up... Possible turn around on a swing trade or investment.

BIVI new 52 lo

BIVI.....Picked up .5250's on Thursday.....Due for a bounce.

BIVI new 52 week lo

BIVI new 52 week low

BIVI new 52=week low

It ran alright ... ran right down to that $1 offering price.

I wonder if this will run on Monday

Impressive Trial Updates

Brave soul...I wouldn't sell till maybe after the conference March 8-9...maybe the 7th...this stock is wound up pretty tight...seems to have lots more upside than down side...

Short

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024

https://finance.yahoo.com/news/biovie-ne3107-demonstrates-potential-improvements-130000143.html

BioVie Shares Double After Positive Data for Parkinson's Disease Treatment


BioVie shares doubled to $2.89 in premarket trading Friday after the company said its Phase 2A study of NE3107 suggested improvements in non-motor symptoms in patients with Parkinson's disease.

The company said these findings complement previously reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity of NE3107 that is consistent with data from animal models.

NE3107-treated patients experienced a significant improvement for the sleep/fatigue domain of the Non-Motor Symptom Scale in Parkinson's disease, whereas placebo patients experienced a worsening.

Sleep/fatigue domain improvements correlated with motor score improvements. More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.


https://www.google.com/amp/s/www.marketwatch.com/amp/story/biovie-shares-double-after-positive-data-for-parkinson-s-disease-treatment-6fca8fee

What leaked?

BIVI new 52 week low

If it is true they can continue the study and add more patients at compliant clinical sites then that is one good reason to buy - after all they have a strong signal already. And of course Ascites...that is bigger than most seem to think.

BIVI seems like a good buy after that sharp drop! I've watched this stock do the same before. After news a huge drop, then a big run! Is there a good reason not to buy BIVI below $2?

https://finance.yahoo.com/news/biovie-bivi-falls-61-despite-152000388.html

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

re. 'single entity?'
Only if the individual sites were all under a single umbrella, which I don't know.
Longer answer: We're talking about this clinical trial.
Now if you look at that trial, you will only find one study location mentioned: The Ohio State University
However, if you look at the history of changes, you'll see the list of locations was deleted by the last change done on November 20, 2023
That's something like, what, 32 sites gone.

Do you think all those clinics were run by a single entity?

Yes, I agree it's not clear. Sorry. The CROs and demographic group are unnamed. I'm guessing the lawyer is filtering those details. Call it Florida/Covid crazy.

FWIW, I don't read a clear explanation just a statement that there were issues. How did 15 clinics fail to follow protocol?

Today's PR clearly explains. See the section 'Data Review and Audit'.
November 29, 2023 PR

How were 80% of patients treated using the wrong protocol or at least no using the approved protocol? How does this happen?

It happens, but also provided a nice trade this am.......

Bulls got slaughtered ouch

@#&%!*........

Didn't wanna cuss.

Freakin' data.

Biovie Webinar:
Date & Time: Dec 7, 2023 03:15 PM Central
Zoom Registration

Peeved, I've never been real big on this one but had hopes without following closely. This latest revelation really puts their credibility on the line

Any thoughts on the blinded data runncoach?

It really looks good imo

Wow. I've never been in this one but that really is potentially about as bad as it gets I would think

This guy with this posting is likely the nature of these 'good clinical practices' irregularities. And before he deletes the post, I've captured the screen.
Actual Twitter Post (while it lasts)
And my copy here.

$BIVI 10-Q issued today.
A section on 'good clinical practices' (GCP) contains the reason for the drop.
Official 10-Q

#bloodbath

Good update from the CEO. Long for the next few years, but I think they'll be many trading opportunities here with quite the volatility in that time frame.

The unblinded results might give BIVI a pop, but I would expect a drop too. It's the nature of these plays.

We'll see.

Aha! Official: just found how to embed yt videos
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=39097864

and it works

Sorry. IHUB tries (and fails) to preview naked YT links.
Let's try this.

Can you edit? The video isn't playing.....

$BIVI promotional update.

Sandbagging? Oh yeah. Expensive lawyers give this advice. lol..

I can't remember the Dr.s name that was on the call that got most of the questions during the Q&A, but he said he had low expectations.

Do you think he was sandbagging?

I'm just playing catch-up here so this is good to me.
They certainly seem excited to be presenting the blinded data.
Like "We don't know" but, really "We know".

I listened live this am. They didn't really tell us anything we didn't know. Maybe the unblinded data will surprise.

Price is holding up pretty well considering, but this has always been a long-term hold for me.

GL

Nov 1 Conference call replay after registration:
https://viavid.webcasts.com/starthere.jsp?ei=1641876&tp_key=48e56ba402

Conference call. 1 p3 done, still blinded. If, after un-blinding, results are as expected, AA may be a path to pursue with FDA. Otherwise a 2nd P3 is on the table.
https://bioviepharma.com/wp-content/uploads/2023/11/BioVie-Conference-Call-2023-11-01.pdf

Posted yesterday about the Conference call…..

The Carson City, Nev.-based clinical-stage pharmaceutical company said Monday morning it would host a conference call Nov. 1 to discuss the blinded data on its Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer's.

Registration details are as follows:
Date November 1, 2023
Time 8:00 AM Eastern Time
Conference Call Details 1-877-407-3982 (U.S. Investors Dial-in)

1-201-493-6780 (International Investors Dial-in)

13742478 (Conference ID Code)

What data are we expecting tomorrow?
The CTAD presentation seemed to be packed with data:
https://www.sec.gov/Archives/edgar/data/1580149/000152013823000457/bivi-20231025_8kex99z1.htm

Hopefully no sell off on the data tomorrow…..

Nice move up today. Hopefully a new trend……